Another Obesity Treatment Approved by the FDA

 

The FDA on Wednesday approved an injection to treat adults who are overweight or obese and have at least one weight-related condition such as high blood pressure or high cholesterol weight for a long time.

The FDA approved Zepbound (tirzepatide) for use in conjunction with a low-calorie diet and plenty of exercise. Tirzepatide is the active ingredient. Mounzaro has already been approved for use in diet and exercise, to improve blood sugar in adults with type 2 diabetes, the FDA said in a press release John Sharretts, M.D. The director of the Drug Evaluation Research Center, FDA's Division of Diabetes, Lipid Disorders and Obesity said: “Obesity and obesity are serious conditions that can be linked to a number of leading causes of death, including heart disease, stroke and diabetes among." “Today’s approval addresses an unmet medical need due to the rising rates of overweight and obesity in the United States.” Consumers have made it popular this year with Vegovi, Ozempic used to treat overweight and obesity and diabetes. About 70% of adults are overweight or obese, and many of those who are overweight have at least one weight-related condition, according to the FDA. Overweight and obese adults can reduce their risk of heart disease by reducing their body weight by 5% to 10% through healthy eating and physical activity. “Zepbound activates pancreatic-derived hormones (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)), Hence decreasing appetite and food intake, the FDA said; ” said the FDA “Zepbound skin once a week It is administered by injection below, and is the maximum dose needed to increase levels over four to 20 weeks to achieve their target dose ocular doses of 5 milligrams (mg), 10 mg or 15 mg once weekly